CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients

Journal of Human Genetics

Volumn 52, Issue 2, 2007, Pages 159-165

  Chakraborty, Anurupa ^a   Murthy, N S ^b   Chintamani, Chintamani ^c   Bhatnagar, D ^c   Mohil, R S ^c   Sharma, P C ^d   Saxena, Sunita ^a  

^a SAFDARJUNG HOSPITAL CAMPUS   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^c SAFDARJUNG HOSPITAL   (India)

^d GURU GOBIND SINGH INDRAPRASTHA UNIVERSITY   (India)

Author keywords

Correlation with ER status; CYP17 gene; Early onset breast cancer; Familial breast cancer; Polymorphism in north Indian population

Indexed keywords

CYTOCHROME P450 17; ESTROGEN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; FISHER EXACT TEST; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIAN; MAJOR CLINICAL STUDY; ONSET AGE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 33846616798     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-006-0095-0     Document Type: Article

References (33)

1. Abrosone BC, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Laughlin R, Nemoto T, Shields PG (1995) Cytochrome P4501A1 and glutathione S-transferase (MI) genetic polymorphism and postmenopausal breast cancer risk. Cancer Res 55:3483-3485
2. Berstein L, Press MF (1998) Does estrogen receptor expression in normal breast tissue predict breast cancer risk? J Natl Cancer Inst 90:5-9
3. Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Marte PM, Piana L (1995) Age as a prognostic factor in breast cancer: relationship to pathology and biological features. Int J Cancer 62:138-144
4. Brentano ST, Picado-Leonard J, Mellon SH, Miller WL, et al (1990) Tissue specific cyclic adenosine 3′5′-monophosphate-induced and phorbol ester repressed transcription from the human P450c17a promoter mouse cell. Mol Endocrinol 4:1972-1979
5. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of steroid metabolism gene CYP 17. Human Mol Genet 3:1873-1876
6. Chako P, Ranjan B, Mathew BS, Joseph T, Pillai MR (2004) CYP17 and SULTIA1 gene polymorphisms in Indian breast cancer. Breast Cancer 11:380-388
7. Clevenger CV (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165:1449-1460
8. Coughlin SS, Piper M (1999) Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomark Prev 8:1023-1320
9. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98:1406-1415
10. Feigelson HS, Henderson BE (1996) Estrogens and breast cancer. Carcinogenesis (Lond) 17:2279-2284
11. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063-1065
12. Feigelson HS, Shames LS, Pike MC, Coetzee GA (1998) Cytochrome P450c17a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585-587
13. Gilbey AM, Burnett D, Coleman RE, Holen I (2004) The detection of circulating breast cancer cells in blood. J Clin Pathol 57:903-911
14. Haiman CA, Hankinson SE, Spiegelman D, et al (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59:1015-1020
15. Hakki T, Bernhardth R (2006) CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther 111:27-52
16. Hanukoglu I (1992) Steroidogenic enzymes, structure, function and role in regulation of steroid hormone biosynthesis. J Steroid Biochem Mol Biol 43:779-804
17. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, et al (1997) An association between the allele coding for a low variant of catecholo-methyltransferase and the risk for breast cancer. Cancer Res 57:5493-5497
18. Lupulescu A (1995) Estrogen use and cancer incidence: a review. Cancer Invest 13:287-295
19. Malin BJ, Massimiliano G, Anna CL, Sten W (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer (Pred Oncol) 84:350-353
20. Myung HS, Kyoung ML, Jung HY, Seok JN, Jong WK, Keun YY, Sue KP, Dong YN (2005) Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med 37:11-17
21. Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogen in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A 92:3650-3657
22. National Cancer Registry Programme (NCRP) (2001) Consolidated report of the population based cancer registries. Indian Council of Medical Research, New Delhi, pp 1990-1996
23. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL (1999) CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res. 59:2825-2828
24. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly Jl, Schnitt S, Abner A, Recht A, Vicini F, Harris JR (1994) Relationship of patient age to pathologic features of tumor and prognosis for patients with stage I and II breast cancer. J Clin Oncol 12:888-894
25. Parkin DM, Whelann SL, Ferlay J, et al. (2002) International Agency for Research on Cancer (IARC). Cancer incidence in five continents vol VIII. IARC, Scientific publication no.155, Lyon, France
26. Picado-Leonard J, Miller WL, et al (1987) Cloning and sequence of the human gene for P450c17a (steroid 17a-hydroxylase/17, 20 lyase): similarity with the gene for P450c21. DNA 6:439-448
27. Pike MC, Pearce CL, Wu AH (2004) Prevention of cancers of the breast, endometrium and ovary. Oncogene 23:6379-6391
28. Sharp L, Cardy AH, Cotton SC, Little J (2004) CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. A HuGE review. Am J Epidemiol 160:729-740
29. Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MRE, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G (2000) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 92:1674-1681
30. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ (1995) A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 55:3757-3758
31. Thompson PA, Shield PG, Freudenheim JL, Stone A, Vena JE (1998) Genetic polymorphism in catechol-O-methyltransferase, menopausal status and breast cancer risk. Cancer Res 58:2107-2110
32. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203-232
33. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spur NK (1993) Relationship between the GSTMI genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14:1821-1824